CORMORANT ASSET MANAGEMENT, LP purchased 8.4% of their position (5.22M shares) of AMBRX BIOPHARMA CAYMAN, INC. on the open market
Open‑market purchase worth $58.95M — a moderate purchase. The strongest form of insider conviction signal.
P · 3 purchases
Filed: 4/20/2023ACC: 0000929638-23-001211
10% Owner
Since Mar 2023
+5.22M
Net shares
Net buyer
$58.95M
Total acquired
3
Open market trades
3B · 0S
3
Total transactions
5.22M acquired
Non-Derivative Transactions3
Ordinary Shares
Indirect
Shares
+3.38M
Price / share
$11.27
Trade value
$38.05M
% of position
5.4%
4/18/2023
62.10M→65.47M
Ordinary Shares
Indirect
Shares
+951.91K
Price / share
$11.15
Trade value
$10.61M
% of position
1.5%
4/19/2023
65.47M→66.43M
Ordinary Shares
Indirect
Shares
+886.63K
Price / share
$11.60
Trade value
$10.29M
% of position
1.3%
4/20/2023
66.43M→67.31M
Total
Net shares
+5.22M
Net value
$58.95M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares Indirect | 4/18/2023 | P · Purchase | +3.38M | $11.27 | $38.05M | 5.4% | 62.10M | 65.47M |
| Ordinary Shares Indirect | 4/19/2023 | P · Purchase | +951.91K | $11.15 | $10.61M | 1.5% | 65.47M | 66.43M |
| Ordinary Shares Indirect | 4/20/2023 | P · Purchase | +886.63K | $11.60 | $10.29M | 1.3% | 66.43M | 67.31M |
| Total | +5.22M | $58.95M | ||||||
Derivative Transactions0
No derivative transactions reported